Placental Derived Natural Killer Cells to Target Solid Tumor Cancer Stem Cells (CSC)
Grant Award Details
Grant Type:
Grant Number:
TRAN1-08635
Investigator(s):
Disease Focus:
Human Stem Cell Use:
Award Value:
$0
Status:
Closed
Grant Application Details
Application Title:
Placental Derived Natural Killer Cells to Target Solid Tumor Cancer Stem Cells (CSC)
Public Abstract:
Translational Candidate
Placental-derived stem cells becoming a unique NK-like cell
Area of Impact
solid tissue cancers
Mechanism of Action
These expanded cells share many characteristics as NK cells but appear to represent a unique stage in differentiation and a cell-type with advantageous properties. These cells have been demonstrated to persist for much longer periods of time in vivo, exhibit broad anti-tumor effects and have a unique phenotype including sustained expression of the Fc receptor, CD16, which is lost on activated mature NK cells.
Unmet Medical Need
Cancer continues to lead as a major cause of mortality in the U.S., the vast majority of cancer patients will relapse and succumb to metastasis. This immunotherapeutic cell therapy in combination with conventional therapies may eradicate the CSC population and result in sustained anti-tumor effects.
Project Objective
preIND
Major Proposed Activities
Placental-derived stem cells becoming a unique NK-like cell
Area of Impact
solid tissue cancers
Mechanism of Action
These expanded cells share many characteristics as NK cells but appear to represent a unique stage in differentiation and a cell-type with advantageous properties. These cells have been demonstrated to persist for much longer periods of time in vivo, exhibit broad anti-tumor effects and have a unique phenotype including sustained expression of the Fc receptor, CD16, which is lost on activated mature NK cells.
Unmet Medical Need
Cancer continues to lead as a major cause of mortality in the U.S., the vast majority of cancer patients will relapse and succumb to metastasis. This immunotherapeutic cell therapy in combination with conventional therapies may eradicate the CSC population and result in sustained anti-tumor effects.
Project Objective
preIND
Major Proposed Activities
- Effects of placental derived stem cell NK cell on solid cancer cell killing & CSC phenotype in vitro
- Effects of placental-derived stem cell NK cell on solid cancer cell killing & CSC phenotype in vivo
- Effects of placental-derived stem cell NK cell on tumor growth & CSC elimination in xenograft models, and prepare and submit preIND package
Statement of Benefit to California:
Cancer continues to lead as a major cause of mortality in the U.S. With advanced disease despite use of extensive conventional cytoreductive cancer therapies, the vast majority of cancer patients will relapse and succumb to metastasis. This unique “off-the-shelf” immunotherapeutic cell therapy product of NK-like cells from placenta derived stem cells could then be used in combination with conventional cancer therapies to eradicate the CSC population and result in sustained anti-tumor effects.